|
1
|
Zou Z and Jemal A: Cancer statistics,
2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Howlader N, Noone AM, Krapcho M, Neyman N,
Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z,
et al: SEER Cancer Statistics Review, 1975–2008, National Cancer
Institute. Bethesda; MD: pp. 192011
|
|
3
|
Milne AN, Sitarz R, Carvalho R, Carneiro F
and Offerhaus GJ: Early onset gastric cancer: On the road to
unraveling gastric carcinogenesis. Curr Mol Med. 7:15–28. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Milne AN, Carneiro F, O'Morain C and
Offerhaus GJ: Nature meets nurture: Molecular genetics of gastric
cancer. Hum Genet. 126:615–628. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Milne AN, Offerhaus GJ and Carneiro F:
Histopathology of familial and early-onset gastric cancer.
Diagnostic Histopathol. 17:62–68. 2011. View Article : Google Scholar
|
|
6
|
Slavin T, Neuhausen SL, Rybak C, Solomon
I, Nehoray B, Blazer K, Niell-Swiller M, Adamson AW, Yuan YC, Yang
K, et al: Genetic gastric cancer susceptibility in the
international clinical cancer genomics community research network.
Cancer Genet. 216–217:111–119. 2017. View Article : Google Scholar
|
|
7
|
Cybulski C, Górski B, Huzarski T, Masojć
B, Mierzejewski M, Debniak T, Teodorczyk U, Byrski T, Gronwald J,
Matyjasik J, et al: CHEK2 is a multiorgan cancer susceptibility
gene. Am J Hum Genet. 75:1131–1135. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Al-Rakan MA, Hendrayani SF and Aboussekhra
A: CHEK2 represses breast stromal fibroblasts and their paracrine
tumor-promoting effects through suppressing SDF-1 and IL-6. BMC
Cancer. 16:5752016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Desrichard A, Bidet Y, Uhrhammer N and
Bignon YJ: CHEK2 contribution to hereditary breast cancer in
non-BRCA families. Breast Cancer Res. 13:R1192011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang N, Ding H, Liu C, Li X, Wei L, Yu J,
Liu M, Ying M, Gao W, Jiang H and Wang Y: A novel recurrent CHEK2
Y390C mutation identified in high-risk Chinese breast cancer
patients impairs its activity and is associated with increased
breast cancer risk. Oncogene. 34:5198–5205. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dong X, Wang L, Taniguchi K, Wang X,
Cunningham JM, McDonnell SK, Qian C, Marks AF, Slager SL, Peterson
BJ, et al: Mutations in CHEK2 associated with prostate cancer risk.
Am J Hum Genet. 72:270–280. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hale V, Weischer M and Park JY: CHEK2 (*)
1100delC mutation and risk of prostate cancer. Prostate Cancer.
2014:2945752014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cybulski C, Masojc B, Oszutowska D,
Jaworowska E, Grodzki T, Waloszczyk P, Serwatowski P, Pankowski J,
Huzarski T, Byrski T, et al: Constitutional CHEK2 mutations are
associated with a decreased risk of lung and laryngeal cancers.
Carcinogenesis. 29:762–765. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kilpivaara O, Alhopuro P, Vahteristo P,
Aaltonen LA and Nevanlinna H: CHEK2 I157T associates with familial
and sporadic colorectal cancer. J Med Genet. 43:e342006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Skierucha M, Milne AN, Offerhaus GJA,
Polkowski WP, Maciejewski R and Sitarz R: Molecular alterations in
gastric cancer with special reference to the early-onset subtype.
World J Gastroenterol. 22:2460–2474. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Teodorczyk U, Cybulski C, Wokołorczyk D,
Jakubowska A, Starzyńska T, Lawniczak M, Domagała P, Ferenc K,
Marlicz K, Banaszkiewicz Z, et al: The risk of gastric cancer in
carriers of CHEK2 mutations. Fam Cancer. 12:473–478. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Buscemi G, Carlessi L, Zannini L, Lisanti
S, Fontanella E, Canevari S and Delia D: DNA damage-induced cell
cycle regulation and function of novel Chk2 phosphoresidues. Mol
Cell Biol. 26:7832–7845, 20060. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
McBride OW, Merry D and Givol D: The gene
for human p53 cellular tumor antigen is located on chromosome 17
short arm (17p13). Proc Natl Acad Sci USA. 83:130–134. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Barnoud T, Parris JLD and Murphy ME:
Common genetic variants in the TP53 pathway and their impact on
cancer. J Mol Cell Biol. 11:578–585. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fenoglio-Preiser CM, Wang J, Stemmermann
GN and Noffsinger A: TP53 and gastric carcinoma: A review. Hum
Mutat. 21:258–270. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Blondal JA and Benchimol S: The role of
p53 in tumor progression. Semin Cancer Biol. 5:177–186.
1994.PubMed/NCBI
|
|
22
|
Lakin ND and Jackson SP: Regulation of p53
in response to DNA damage. Oncogene. 18:7644–7655. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Laurén P: The two histological main types
of gastric carcinoma: Diffuse and so-called intestinal-type
carcinoma. An attempt at a histo-clinical classification. Acta
Pathol Microbiol Scand. 64:31–49. 1965. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Milne AN, Carvalho R, Morsink FM, Musler
AR, de Leng WW, Ristimäki A and Offerhaus GJ: Early-onset gastric
cancers have a different molecular expression profile than
conventional gastric cancers. Mod Pathol. 19:564–572. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sitarz R, Leguit RJ, de Leng WW, Polak M,
Morsink FM, Bakker O, Maciejewski R, Offerhaus GJ and Milne AN: The
COX-2 promoter polymorphism-765 G>C is associated with
early-onset, conventional and stump gastric cancers. Mod Pathol.
21:685–690. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li H, Handsaker B, Wysoker A, Fennell T,
Ruan J, Homer N, Marth G, Abecasis G and Durbin R; 1000 Genome
Project Data Processing Subgroup, : The sequence Alignment/Map
format and SAMtools. Bioinformatics. 25:2078–2079. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
McKenna A, Hanna M, Banks E, Sivachenko A,
Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly
M and DePristo MA: The genome analysis toolkit: A MapReduce
framework for analyzing next-generation DNA sequencing data. Genome
Res. 20:1297–1303. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Narzisi G, O'Rawe JA, Iossifov I, Fang H,
Lee YH, Wang Z, Wu Y, Lyon GJ, Wigler M and Schatz MC: Accurate de
novo and transmitted indel detection in exome-capture data using
microassembly. Nat Methods. 11:1033–1036. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cingolani P, Platts A, Wang le L, Coon M,
Nguyen T, Wang L, Land SJ, Lu X and Ruden DM: A program for
annotating and predicting the effects of single nucleotide
polymorphisms, SnpEff: SNPs in the genome of Drosophila
melanogaster strain w1118; iso-2; iso-3. Fly (Austin). 6:80–92.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rugge M, Shiao YH, Busatto G, Cassaro M,
Strobbe C, Russo VM, Leo G, Parenti AR, Scapinello A, Arslan P and
Egarter-Vigl E: The p53 gene in patients under the age of 40 with
gastric cancer: Mutation rates are low but are associated with a
cardiac location. Mol Pathol. 53:207–210. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xu JH, Chen LR, Wang HJ and Yao LF:
Application of immunohistochemistry-Laser microdissection-PCR
technique in detecting p53 gene mutation in paraffin sections of
gastric cancer. Zhonghua Bing Li Xue Za Zhi. 33:342–345. 2004.(In
Chinese). PubMed/NCBI
|
|
32
|
Gleeson CM, Sloan JM, McManus DT, Maxwell
P, Arthur K, McGuigan JA, Ritchie AJ and Russell SE: Comparison of
p53 and DNA content abnormalities in adenocarcinoma of the
oesophagus and gastric cardia. Br J Cancer. 77:277–286. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kim SS, Bhang CS, Min KO, Chae HS, Choi
SW, Lee CD, Lim KW, Chung IS and Park DH: p53 mutations and
microsatellite instabilities in the subtype of intestinal
metaplasia of the stomach. J Korean Med Sci. 17:490–496. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bartek J and Lukas J: Chk1 and Chk2
kinases in checkpoint control and cancer. Cancer Cell. 3:421–429.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cybulski C, Wokołorczyk D, Jakubowska A,
Huzarski T, Byrski T, Gronwald J, Masojć B, Deebniak T, Górski B,
Blecharz P, et al: Risk of breast cancer in women with a CHEK2
mutation with and without a family history of breast cancer. J Clin
Oncol. 29:3747–3752. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Siołek M, Cybulski C, Gąsior-Perczak D,
Kowalik A, Kozak-Klonowska B, Kowalska A, Chłopek M, Kluźniak W,
Wokołorczyk D, Pałyga I, et al: CHEK2 mutations and the risk of
papillary thyroid cancer. Int J Cancer. 137:548–552. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zoppoli G, Solier S, Reinhold WC, Liu H,
Connelly JW Jr, Monks A, Shoemaker RH, Abaan OD, Davis SR, Meltzer
PS, et al: CHEK2 genomic and proteomic analyses reveal genetic
inactivation or endogenous activation across the 60 cell lines of
the US National Cancer Institute. Oncogene. 31:403–418. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li J and Stern DF: DNA damage regulates
Chk2 association with chromatin. J Biol Chem. 280:37948–37956.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ćmielová J, Lesná M and Řezáčová M:
Subcellular localization of proteins responding to
mitoxantrone-induced DNA damage in leukaemic cells. Folia Biol
(Praha). 61:60–65. 2015.PubMed/NCBI
|
|
40
|
Li WQ, Hu N, Hyland PL, Gao Y, Wang ZM, Yu
K, Su H, Wang CY, Wang LM, Chanock SJ, et al: Genetic variants in
DNA repair pathway genes and risk of esophageal squamous cell
carcinoma and gastric adenocarcinoma in a Chinese population.
Carcinogenesis. 34:1536–1542. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lane DP: Cancer. p53, guardian of the
genome. Nature. 358:15–16. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Vousden KH and Prives C: P53 and
prognosis: New insights and further complexity. Cell. 120:7–10.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Feng Z, Hu W, Teresky AK, Hernando E,
Cordon-Cardo C and Levine AJ: Declining p53 function in the aging
process: A possible mechanism for the increased tumor incidence in
older populations. Proc Natl Acad Sci USA. 104:16633–16638. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
DiTullio RA Jr, Mochan TA, Venere M,
Bartkova J, Sehested M, Bartek J and Halazonetis TD: 53BP1
functions in an ATM-dependent checkpoint pathway that is
constitutively activated in human cancer. Nat Cell Biol.
4:998–1002. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
46
|
Steels E, Paesmans M, Berghmans T, Branle
F, Lemaitre F, Mascaux C, Meert AP, Vallot F, Lafitte JJ and
Sculier JP: Role of p53 as a prognostic factor for survival in lung
cancer: A systematic review of the literature with a meta-analysis.
Eur Respir J. 18:705–719. 2001. View Article : Google Scholar : PubMed/NCBI
|
